MS Patients Show Greater Risk of Infections Before and After Diagnosis, Study Finds

MS Patients Show Greater Risk of Infections Before and After Diagnosis, Study Finds
4.6
(14)

Multiple sclerosis (MS) patients have a greater risk of infections, particularly urinary and kidney infections, around the time of their diagnosis, compared with individuals without MS, a large Swedish population-based study found.

Rates of serious and non-serious infections, as well as infections caused by bacteria, virus, and fungus, also were higher in these patients, researchers reported.

The study, “Infections in patients with multiple sclerosis: A national cohort study in Sweden,” was published in the journal Multiple Sclerosis and Related Disorders.

Compared to the public at large, MS patients are thought to be at increased risk of infections because MS disease-modifying therapies used to lower relapse rates act by dampening the immune system.

But studies investigating the rates of incident infections in MS patients are rare.

Researchers in Sweden now have conducted a large population-based study to determine the rates of infections before and after an MS diagnosis, compared with matched individuals without MS. Their analysis was categorized by age and sex.

In total, the study included 6,602 adult MS patients, diagnosed from 2008 to 2016, and 61,828 controls without MS, who were matched to patients in terms of age, sex, and region (county) of residence at the time of MS diagnosis. For each patient, about 10 matched controls were included in the analysis.

Results showed that in the year before their diagnosis, MS patients already had a significantly higher rate of infections, including those of the urinary tract and kidneys, respiratory and throat infections, meningitis and encephalitis, bacterial infectious diseases, and herpes virus infections.

Among MS patients, urinary and kidney infections were more common in women and in patients age 60 or older. Respiratory and throat infections also were more common in women.

Investigators then assessed the rate of first infections occurring after the MS diagnosis, and whether some specific infections were more common in MS patients. This last assessment was done via the incidence rate ratio (IRR), which compares incidence rates in two distinct populations.

Of note, an IRR of 1 means an identical incidence rate in both populations;  greater than 1 means the incidence is greater in MS patients, and lower than 1 defines a greater incidence in controls.

Like in the year prior to their diagnosis, MS patients also had significantly more first infections after their diagnosis compared with controls. The incidence of serious infections was 2.5 times higher in patients than in controls, and non-serious first infections were 1.6 times more common in patients.

MS patients had a greater incidence of many kinds of first infections, including skin, respiratory and throat infections, pneumonia and influenza,  bacterial, viral, and fungal infections. The greatest difference in incidence, however, was seen for urinary and kidney infections, which were 2.44 more common in patients.

All the aforementioned infections, except skin infections, had higher IRR in men than in women with MS. Meningitis and encephalitis, two inflammations of the brain, were greater only in MS patients younger than 60.

The cumulative incidence — essentially the proportion of patients who developed an infection within a certain period of time — of urinary and kidney infections, skin infections, respiratory and throat infections, pneumonia and influenza, meningitis and encephalitis, bacterial and viral infections, also was greater for MS patients in the first five years within their diagnosis and in the five years that followed, compared to controls.

Cumulative incidence for fungal infections, herpes virus infections, and other opportunistic infections was significantly higher only for patients in the first five years after their diagnosis.

Consistent with the greater incidence of infections, MS patients used anti-infective medications — specifically anti-bacterial medications — significantly more frequently than controls both before and after their diagnosis.

“In this population-based, national cohort study, patients with newly diagnosed MS had an increased risk of several incident infections, compared with matched MS-free individuals,” the researchers wrote. “The increased rate of infections immediately before MS diagnosis indicates greater susceptibility in MS patients even before treatment using DMTs and before the disease progresses.”

The team acknowledged that the higher incidence of infections in MS patients may be due to closer observation by physicians given the frequent visits needed to manage these patients, but believe that this could explain only a small difference, as the cumulative incidence also was higher in these patients.

“In conclusion, the burden of infections around the time of MS diagnosis and subsequent infection risk underscore the need for careful considerations regarding the risk-benefit across different DMTs, but also refining further preventive strategies to limit risks,” the team concluded.

Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
Total Posts: 1,053
Patrícia holds her PhD in Medical Microbiology and Infectious Diseases from the Leiden University Medical Center in Leiden, The Netherlands. She has studied Applied Biology at Universidade do Minho and was a postdoctoral research fellow at Instituto de Medicina Molecular in Lisbon, Portugal. Her work has been focused on molecular genetic traits of infectious agents such as viruses and parasites.
×
Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
Latest Posts
  • PoNS device
  • QuadraMune patent filing
  • Ocrevus and infection risk
  • tolebrutinib and myelin

How useful was this post?

Click on a star to rate it!

Average rating 4.6 / 5. Vote count: 14

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?